Baird Financial Group
EGRX

Baird Financial Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Baird Financial Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36,747
Closed -$1.76M – 1589
2020
Q2 		$1.76M Buy
36,747
+910
+3% +$45.4K 0.01% 759
2020
Q1 		$1.65M Buy
35,837
+88
+0.2% +$4.42K 0.01% 744
2019
Q4 		$2.15M Buy
35,749
+4,107
+13% +$245K 0.01% 755
2019
Q3 		$1.79M Buy
31,642
+1,210
+4% +$68K 0.01% 806
2019
Q2 		$1.7M Sell
30,432
-1,653
-5% -$86.2K 0.01% 830
2019
Q1 		$1.62M Sell
32,085
-2,079
-6% -$92.5K 0.01% 729
2018
Q4 		$1.38M Sell
34,164
-87
-0.3% -$4.48K 0.01% 721
2018
Q3 		$2.32M Buy
34,251
+489
+1% +$37.1K 0.01% 623
2018
Q2 		$2.55M Buy
33,762
+44
+0.1% +$2.77K 0.02% 599
2018
Q1 		$1.78M Buy
33,718
+105
+0.3% +$6.11K 0.01% 663
2017
Q4 		$1.8M Sell
33,613
-104
-0.3% -$5.79K 0.01% 660
2017
Q3 		$2.01M Sell
33,717
-170
-0.5% -$10.3K 0.02% 617
2017
Q2 		$2.67M Sell
33,887
-86
-0.3% -$7.03K 0.02% 532
2017
Q1 		$2.82M Buy
33,973
+451
+1% +$33.5K 0.02% 516
2016
Q4 		$2.66M Buy
+33,522
New +$2.44M 0.02% 508

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baird Financial Group's EGRX Position: Q3 2020 in Review

Baird Financial Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2020, closing a stake of 36,747 shares — an estimated $1.76M sold.

Baird Financial Group first reported a position in EGRX in Q4 2016 and held it in 15 quarters. The position peaked at $2.82M in Q1 2017. 171 funds tracked by Wall St. Rank hold EGRX as of Q3 2020.

  • Baird Financial Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Baird Financial Group sold 36,747 Eagle Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.76M.
  • Baird Financial Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 15 quarters.
  • Baird Financial Group's Eagle Pharmaceuticals, Inc. position peaked at $2.82M in Q1 2017.
  • 171 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2020.

Based on Baird Financial Group's 13F filing for Q3 2020, filed 12 Nov 2020.